{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:05:16Z","timestamp":1784732716490,"version":"3.55.0"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"unspecified","delay-in-days":81,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020799","name":"Association des Scl\u00e9rodermiques de France","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020799","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CPER ResIsT-omics","award":["22-C-0128"],"award-info":[{"award-number":["22-C-0128"]}]},{"name":"Chair AI and Health ARCHIE from University of Lille","award":["I-KUL-22-005-ARCHIE-INFINITE"],"award-info":[{"award-number":["I-KUL-22-005-ARCHIE-INFINITE"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,1,28]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Antinuclear antibodies (ANA) are powerful biomarkers in systemic sclerosis (SSc). Functional antibodies (FA) might be implicated in vasculopathy, in which endothelial cells (EC) are key players. We aimed to explore the effect of purified IgG from patients with SSc on omics signatures of EC and examine the influence of ANA serotypes and FA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>EC were cultured in the presence of purified IgG from patients with SSc, patients with systemic lupus erythematosus (SLE) or healthy controls (HC). EC omics profiles were analysed by liquid chromatography with tandem mass spectrometry (LC-MS\/MS) and RNA sequencing. EC proteome induced by IgG from patients with SSc was confirmed with an external validation cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the derivation cohort, principal component analysis (PCA) using proteomics data showed three distinct groups of subjects: a first one including mostly anti-topoisomerase-I positive patients (ATA+), a second one including mostly anti-centromere positive patients and a third group comprising anti-RNA polymerase-III positive patients, SLE and HC. In transcriptomics, PCA distinguished one group composed of ATA+patients\u2009only from a second group mixing ATA+patients with other individuals. The validation cohort confirmed the existence of two groups of distinct EC proteome profiles and clinical severity in ATA+patients. In both SSc cohorts, no association between FA presence and proteomic profiles was observed. Quantitative proteomics measured the most discriminant proteins in EC exposed to purified IgG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Purified IgG from patients with SSc can modify EC proteome and transcriptome. The observed changes closely associate with ANA serotype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-004290","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T04:56:00Z","timestamp":1742705760000},"page":"e004290","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Immunoglobulins G from Patients with Systemic Sclerosis Modify the Molecular Signatures of Endothelial Cells"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04334031","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-5983","authenticated-orcid":false,"given":"Aur\u00e9lien","family":"Chepy","sequence":"first","affiliation":[{"name":"Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France"},{"name":"CHU Lille, D\u00e9partement de M\u00e9decine Interne et Immunologie Clinique, Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, M\u00e9diterran\u00e9e et Guadeloupe (CeRAINOM), Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Vivier","sequence":"additional","affiliation":[{"name":"Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Bray","sequence":"additional","affiliation":[{"name":"Univ. Lille, CNRS, USR 3290 - MSAP - Miniaturisation pour la Synth\u00e8se, l'Analyse et la Prot\u00e9omique, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Chauvet","sequence":"additional","affiliation":[{"name":"Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Lescoat","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne et Immunologie Clinique, CHU Rennes, Universit\u00e9 Rennes, Rennes, France"},{"name":"Inserm, EHESP, Irset (Institut de Recherche en Sant\u00e9, Environnement et Travail) - UMR_S 1085, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderrahmane","family":"Elhannani","sequence":"additional","affiliation":[{"name":"Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France"},{"name":"CHU Lille, D\u00e9partement de M\u00e9decine Interne et Immunologie Clinique, Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, M\u00e9diterran\u00e9e et Guadeloupe (CeRAINOM), Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Figeac","sequence":"additional","affiliation":[{"name":"Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Guilbert","sequence":"additional","affiliation":[{"name":"Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France"},{"name":"CHU Lille, Institut d\u2019Immunologie, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Lepr\u00eatre","sequence":"additional","affiliation":[{"name":"Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Bourel","sequence":"additional","affiliation":[{"name":"Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[{"name":"Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France"},{"name":"CHU Lille, D\u00e9partement de M\u00e9decine Interne et Immunologie Clinique, Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, M\u00e9diterran\u00e9e et Guadeloupe (CeRAINOM), Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rolando","sequence":"additional","affiliation":[{"name":"Univ. Lille, CNRS, USR 3290 - MSAP - Miniaturisation pour la Synth\u00e8se, l'Analyse et la Prot\u00e9omique, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Lecureur","sequence":"additional","affiliation":[{"name":"Inserm, EHESP, Irset (Institut de Recherche en Sant\u00e9, Environnement et Travail) - UMR_S 1085, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Dubucquoi","sequence":"additional","affiliation":[{"name":"Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France"},{"name":"CHU Lille, Institut d\u2019Immunologie, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Launay","sequence":"additional","affiliation":[{"name":"Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France"},{"name":"CHU Lille, D\u00e9partement de M\u00e9decine Interne et Immunologie Clinique, Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, M\u00e9diterran\u00e9e et Guadeloupe (CeRAINOM), Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3083-2441","authenticated-orcid":false,"given":"Vincent","family":"Sobanski","sequence":"additional","affiliation":[{"name":"Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France"},{"name":"CHU Lille, D\u00e9partement de M\u00e9decine Interne et Immunologie Clinique, Centre de R\u00e9f\u00e9rence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, M\u00e9diterran\u00e9e et Guadeloupe (CeRAINOM), Lille, France"},{"name":"Institut Universitaire de France (IUF), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,23]]},"reference":[{"key":"2025121606200654000_11.1.e004290.1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"The Lancet"},{"key":"2025121606200654000_11.1.e004290.2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.930970"},{"key":"2025121606200654000_11.1.e004290.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-015-0513-5"},{"key":"2025121606200654000_11.1.e004290.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.38098"},{"key":"2025121606200654000_11.1.e004290.5","doi-asserted-by":"crossref","first-page":"904631","DOI":"10.3389\/fimmu.2022.904631","article-title":"Effects of Immunoglobulins G From Systemic Sclerosis Patients in Normal Dermal Fibroblasts: A Multi-Omics Study","volume":"13","author":"Chepy","year":"2022","journal-title":"Front Immunol"},{"key":"2025121606200654000_11.1.e004290.6","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btq054"},{"key":"2025121606200654000_11.1.e004290.7","doi-asserted-by":"publisher","DOI":"10.2202\/1544-6115.1027"},{"key":"2025121606200654000_11.1.e004290.8","doi-asserted-by":"crossref","unstructured":"Love MI , Huber W , Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014;15. doi:10.1186\/s13059-014-0550-8","DOI":"10.1186\/s13059-014-0550-8"},{"key":"2025121606200654000_11.1.e004290.9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005752","article-title":"mixOmics: An R package for \u2019omics feature selection and multiple data integration","volume":"13","author":"Rohart","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"2025121606200654000_11.1.e004290.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1995.tb02031.x)"},{"key":"2025121606200654000_11.1.e004290.11","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat Commun"},{"key":"2025121606200654000_11.1.e004290.12","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/art.40906","article-title":"Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis","volume":"71","author":"Sobanski","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025121606200654000_11.1.e004290.13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1045523","article-title":"Comprehensive autoantibody profiles in systemic sclerosis: Clinical cluster analysis","volume":"13","author":"H\u00f6ppner","year":"2022","journal-title":"Front Immunol"},{"key":"2025121606200654000_11.1.e004290.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214202","article-title":"Autoantibodies are present before the clinical diagnosis of systemic sclerosis","volume":"14","author":"Burbelo","year":"2019","journal-title":"PLoS One"},{"key":"2025121606200654000_11.1.e004290.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.06.010"},{"key":"2025121606200654000_11.1.e004290.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102659"},{"key":"2025121606200654000_11.1.e004290.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.22747"},{"key":"2025121606200654000_11.1.e004290.18","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/art.41403","article-title":"Association of Anti-Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti-Topoisomerase I-Positive Systemic Sclerosis","volume":"72","author":"Boonstra","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025121606200654000_11.1.e004290.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61159-3","article-title":"Levels of anti-topoisomerase I antibody correlated with short onset of cardiopulmonary involvement in Thai systemic sclerosis patients","volume":"14","author":"Mulalin","year":"2024","journal-title":"Sci Rep"},{"key":"2025121606200654000_11.1.e004290.20","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/rheumatology\/keaa447","article-title":"Association of differentially expressed genes and autoantibody type in patients with systemic sclerosis","volume":"60","author":"Inamo","year":"2021","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025121606200654000_11.1.e004290.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224184"},{"key":"2025121606200654000_11.1.e004290.22","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"The Lancet Rheumatology"},{"key":"2025121606200654000_11.1.e004290.23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamadermatol.2022.6340","article-title":"Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis: Follow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels","volume":"159","author":"Kuzumi","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2025121606200654000_11.1.e004290.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225174"},{"key":"2025121606200654000_11.1.e004290.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917"},{"key":"2025121606200654000_11.1.e004290.26","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000134644.89917.96"},{"key":"2025121606200654000_11.1.e004290.27","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1234104","article-title":"Molecular mechanism of VE-cadherin in regulating endothelial cell behaviour during angiogenesis","volume":"14","author":"Nan","year":"2023","journal-title":"Front Physiol"},{"key":"2025121606200654000_11.1.e004290.28","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02360-3","article-title":"Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis","volume":"22","author":"Raschi","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025121606200654000_11.1.e004290.29","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12061331","article-title":"Recent Insights into Cellular and Molecular Mechanisms of Defective Angiogenesis in Systemic Sclerosis","volume":"12","author":"Romano","year":"2024","journal-title":"Biomedicines"},{"key":"2025121606200654000_11.1.e004290.30","doi-asserted-by":"crossref","unstructured":"Rouvi\u00e8re B , Le Dantec C , Bettacchioli E , et al . Stratification according to autoantibody status in systemic sclerosis reveals distinct molecular signatures. Ann Rheum Dis 2024:ard-2024-225925. doi:10.1136\/ard-2024-225925","DOI":"10.1136\/ard-2024-225925"},{"key":"2025121606200654000_11.1.e004290.31","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2011.158"},{"key":"2025121606200654000_11.1.e004290.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65284-4"},{"key":"2025121606200654000_11.1.e004290.33","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.21.13313"},{"key":"2025121606200654000_11.1.e004290.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2004.08.018"},{"key":"2025121606200654000_11.1.e004290.35","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.788250","article-title":"Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies","volume":"8","author":"Zanin-Silva","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025121606200654000_11.1.e004290.36","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1093\/rheumatology\/kead060","article-title":"Detection of anti-eIF2B autoantibodies in systemic sclerosis by immunoprecipitation-mass spectrometry","volume":"62","author":"Vulsteke","year":"2023","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025121606200654000_11.1.e004290.37","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1093\/rheumatology\/kead649","article-title":"ELISA detection of anti-eIF2B antibodies in Japanese patients with systemic sclerosis","volume":"63","author":"Koizumi","year":"2024","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025121606200654000_11.1.e004290.38","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1021\/acs.jproteome.3c00268","article-title":"Identification of Anti-SNRPA as a Novel Serological Biomarker for Systemic Sclerosis Diagnosis","volume":"22","author":"Liu","year":"2023","journal-title":"J Proteome Res"},{"key":"2025121606200654000_11.1.e004290.39","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.674523","article-title":"Expression and Pathogenic Analysis of Integrin Family Genes in Systemic Sclerosis","volume":"8","author":"Xu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025121606200654000_11.1.e004290.40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.102961","article-title":"Serine\/threonine-protein kinase STK24 induces tumorigenesis by regulating the STAT3\/VEGFA signaling pathway","volume":"299","author":"Lai","year":"2023","journal-title":"J Biol Chem"},{"key":"2025121606200654000_11.1.e004290.41","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.5152\/eurjrheum.2020.19131","article-title":"Putative functional pathogenic autoantibodies in systemic sclerosis","volume":"7","author":"Benfaremo","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"2025121606200654000_11.1.e004290.42","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135772"},{"key":"2025121606200654000_11.1.e004290.43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-222088"},{"key":"2025121606200654000_11.1.e004290.44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.786039","article-title":"Functionally Active Antibodies to the Angiotensin II Type 1-Receptor Measured by a Luminometric Bioassay Do Not Correlate With Clinical Manifestations in Systemic Sclerosis: A Comparison With Antibodies to Vascular Receptors and Topoisomerase I Detected by ELISA","volume":"12","author":"Bankamp","year":"2021","journal-title":"Front Immunol"},{"key":"2025121606200654000_11.1.e004290.45","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/rheumatology\/keac549","article-title":"Functional autoantibodies in systemic sclerosis: influence of autologous stem cell transplantation and correlation with clinical outcome","volume":"62","author":"Bankamp","year":"2023","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025121606200654000_11.1.e004290.46","doi-asserted-by":"publisher","DOI":"10.1002\/art.21646"},{"key":"2025121606200654000_11.1.e004290.47","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1689-6","article-title":"Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts","volume":"20","author":"Raschi","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025121606200654000_11.1.e004290.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2004.11.008"},{"key":"2025121606200654000_11.1.e004290.49","article-title":"Pathogenic autoantibody internalization in myositis","volume":"17","author":"Pinal-Fernandez","year":"2024","journal-title":"medRxiv"},{"key":"2025121606200654000_11.1.e004290.50","doi-asserted-by":"crossref","first-page":"150123","DOI":"10.1016\/j.bbrc.2024.150123","article-title":"Nuclear-penetrating scleroderma autoantibody inhibits topoisomerase 1 cleavage complex formation","volume":"720","author":"May","year":"2024","journal-title":"Biochem Biophys Res Commun"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-004290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T14:20:20Z","timestamp":1765894820000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-004290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3,23]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/rmdopen-2024-004290"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-004290","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}